Glucosamine Hydrochloride

DUBLIN, March 26, 2024 /PRNewswire/ -- The "Chondroitin Sulfate for Pet Supplements Market - Forecasts from 2024 to 2029" report has been added to ResearchAndMarkets.com's offering. Chondroitin sulfate, a natural compound present in cartilage, the protective tissue surrounding bones in joints, is a prevalent ingredient in pet supplements aimed at promoting joint health, particularly for dogs and cats grappling with osteoarthritis (OA). Pet owners often turn to daily joint supplements when addressing bone and joint diseases in their pets. These supplements, known as chondroprotective, also find use in mitigating inflammation in various bodily areas, particularly those exposed to fluids or mucus. For instance, pets with frequent urination due to an irritated bladder lining can benefit from formulations containing glucosamine and chondroitin. Many pet owners prefer chondroprotective like glucosamine and chondroitin due to their holistic approach, promoting overall pet well-being rather than merely alleviating symptoms. Additionally, these supplements tend to have few side effects and enable pets to rely less on prescription medications. Importantly, chondroprotective supplements are generally considered safe for long-term use, potentially for a pet's lifespan. It is advisable to administer chondroitin supplements in response to joint injuries, initiating joint supplements early in a pet's life is also recommended as a preventive measure. Market Drivers Rise in Pet Ownership Worldwide, there is a growing trend of integrating pets into changing lifestyles, with pets becoming integral companions across the globe. The COVID-19 pandemic witnessed an upswing in pet adoption, notably in the United States, where the percentage of households with at least one dog increased from 38% to 45% between 2016 and 2020, and cat ownership experienced a steady rise from 25% to 29% in 2022. In China, 74 million households own dogs, the United States has 85 million dog owners, and the European Union boasts 92 million dog owners. These figures underscore the global significance of pets and their impact on the chondroitin sulfate market. Growing awareness of the significance of chondroitin sulfate Chondroitin sulfate is gaining popularity in the pet supplement sector as awareness grows regarding its potential advantages for enhancing joint health in dogs and cats. Faced with concerns about possible side effects, pet owners are increasingly inclined toward natural methods to address their pet's well-being. Chondroitin sulfate, sourced from natural origins such as cartilage and shellfish, aligns with this preference, presenting a potentially safer alternative. Pet caregivers are becoming increasingly cognizant of the adverse impact of osteoarthritis (OA) on their pets' quality of life. Market Challenges Regulatory challenges posing a hurdle Navigating regulatory challenges poses an obstacle in the realm of pet supplements. At present, AAFCO exclusively oversees the labelling of supplements categorized as "food-type". Despite a growing body of scientific information on veterinary pet supplements and nutraceuticals, there persists a scarcity of quality control, safety, and efficacy data for the majority of these marketed substances and the corresponding products available for purchase. Despite this evidence gap, the utilization of veterinary supplements and nutraceuticals is on the rise. It is imperative for veterinarians and pet owners alike to advocate for enhanced enforcement of regulations governing these products and to call for manufacturers to collaborate more closely with researchers for the betterment of pets as well as the market. By pet type, chondroitin sulfate for the pet supplements market is divided into dogs and cats The chondroitin sulfate for the pet supplement market is segmented into two categories, i.e, dogs and cats- In the United States, 65.1 million households consider dogs integral family members. The feline companionship is also cherished, as revealed by the 46.5 million households that own a cat, according to the American Pet Products Association (APPA). Notably, the APPA highlights that a significant portion of pet owners in the U.S. are millennials, underscoring the growing importance of pets in the lives of this demographic. Europe is anticipated to hold a notable share of the chondroitin sulfate for pet supplements Europe is projected to account for a notable share of the chondroitin sulfate for pet supplements owing to the people's huge ownership of pets in these regions. As the FEDIAF Facts & Figures states the expanding landscape of pet ownership in Europe, indicates that 90 million households in the European Union have embraced the companionship of a pet, representing 46% of households. The breakdown of this pet population reveals approximately 110 million cats, 90 million dogs, 50 million birds, 30 million small mammals, 15 million aquariums, and 10 million terrariums, showcasing the diverse array of pets that contribute to the rich tapestry of European households. Market Segmentation By Purity Level 99% Level Others By Pet Type Cat Dog By Geography North America USA Others Europe, Middle East, And Africa UK Germany France Others Asia Pacific China Japan South Korea Others Companies Profiled Unibridge Shandong Haiyu Biological Co., Ltd ZPD A/S Shandong Runxin Biotechnology Co., Ltd Bioiberica S.A.U. For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

精彩内容近几年随着社会老龄化加快，肌肉-骨骼系统相关药物需求大增，已成为炙手可热的药品大类。江苏正大清江制药积极掘金这个400亿市场，2023年上半年在抗炎抗风湿药市场的排名再创新高，首款1类新药已进入临床，将开拓抗痛风制剂市场，目前报产在审的6个新品中有两个为肌肉松弛药，将助力公司进军这个火热市场。公司积极参与国家集中带量采购，第十批国采如箭在弦，重磅新品即将迎战。抗炎抗风湿药持续走高，抢10亿品种国内首仿江苏正大清江制药是国内知名的骨科药物研发与生产基地之一，是正大制药集团旗下企业。米内网数据显示，在中国公立医疗机构终端及中国城市实体药店终端抗炎抗风湿药市场，江苏正大清江制药的排名不断上升。表1：2023年上半年江苏正大清江制药在抗炎抗风湿药市场的情况来源：米内网格局数据库图1：江苏正大清江制药已获批的抗炎抗风湿药来源：米内网中国上市药品（MID）数据库目前江苏正大清江制药已拥有3款抗炎抗风湿药的生产批文，其中盐酸氨基葡萄糖片已成为公司的拳头产品。2020-2022年在中国公立医疗机构终端（城市公立医院+县级公立医院+城市社区中心+乡镇卫生院），公司的盐酸氨基葡萄糖片销售额保持在3亿元以上，2023年上半年增长率为44.53%；在中国城市实体药店终端，2022年公司的盐酸氨基葡萄糖片销售额突破1.4亿元，2023年上半年增长率为37.12%。塞来昔布胶囊是江苏正大清江制药在2019年获批的新产品，2021-2022年在中国公立医疗机构终端，公司的塞来昔布胶囊销售额增长率分别为19.57%、23.27%，2023年上半年再有24.97%的增长；在中国城市实体药店终端，2021-2022年公司的塞来昔布胶囊销售额增长率均超过100%，2023年上半年再有12.21%的增长。拳头产品稳中有升，潜力产品迅速扩张，助力江苏正大清江制药不断提升市场地位。2022年10月，公司提交了艾拉莫德片的4类仿制上市申请，该产品是先声药业的国产原研药，可用于治疗活动性类风湿关节炎。图2：艾拉莫德片在中国三大终端六大市场的销售情况（单位：万元）来源：米内网格局数据库艾拉莫德片2022年在中国三大终端六大市场的合计销售额已涨至11亿元以上，其中公立医院终端（城市公立医院+县级公立医院）是销售主战场。目前该产品暂未有国产仿制药获批，3家国内药企提交了4类仿制上市申请并在审评审批中，江苏正大清江制药抢首仿有时间优势。若艾拉莫德片最终顺利获批，江苏正大清江制药的抗炎抗风湿药产品矩阵将增添一员猛将，公司的市场地位有望进一步提升。首款1类新药出击，剑指抗痛风制剂市场抗痛风制剂是肌肉-骨骼系统药物中重要的亚类之一，随着生活水平提高，人们摄入高糖、高脂肪食物以及高嘌呤食物明显增加，中国高尿酸血症、痛风患病人数呈增加趋势，该类药物的市场潜力不容小觑。目前江苏正大清江制药暂无抗痛风制剂上市销售，2023年公司的1类新药QJ-19-0002片申报临床并获批，拟用于高尿酸血症和痛风的治疗。图3：QJ-19-0002片的项目情况来源：米内网项目进度数据库QJ-19-0002片是江苏正大清江制药的首款1类新药，为新一代尿酸排泄促进剂，通过靶向抑制URAT1使尿液尿酸盐排泄正常化，从而降低血清尿酸水平。该新药在2023年年底启动了I期临床，标志着公司的创新研发从“仿制为主”逐步向“仿创结合”迈进。据悉，江苏正大清江制药的研发重点围绕骨科和儿科两大核心领域，并积极开拓精麻类、眼科类等用药领域，同时不断丰富产品剂型。6大新品冲刺上市，肌肉松弛药市场迎新突破2022年中国三大终端六大市场化学药（含生物药）市场肌肉-骨骼系统药物的合计销售规模已涨至420亿元以上，抗炎药和抗风湿药是TOP1亚类，合计销售规模已超过200亿元，肌肉松弛药、抗痛风制剂两大亚类市场近几年也逐渐火热。江苏正大清江制药目前已进入了抗炎抗风湿药市场的领先企业梯队，排名逐年上升，首款1类新药将为公司打开抗痛风制剂市场大门，而报产在审的产品中罗库溴铵注射液和美索巴莫注射液也将成为公司打开肌肉松弛药市场的“钥匙”。表2：江苏正大清江制药2022年至今报产在审的新产品来源：米内网中国申报进度（MED）数据库罗库溴铵和美索巴莫是肌肉松弛药畅销品种，2022年在中国三大终端六大市场罗库溴铵的合计销售规模在10亿元以上、美索巴莫的合计销售规模也达到了3亿元以上，若江苏正大清江制药的罗库溴铵注射液和美索巴莫注射液能顺利获批，将为公司在肌肉松弛药打下坚实的基础。8个产品已过评，$20亿品种备战第十批国采2019年12月，江苏正大清江制药的塞来昔布胶囊4类仿制上市申请获批并视同过评，成为了公司首个过评产品，截至2024年3月8日，公司已过评（含视同过评）的产品数量为8个。表3：江苏正大清江制药已过评/视同过评的产品来源：米内网中国申报进度（MED）数据库2020年8月第三批国采如约而至，江苏正大清江制药的盐酸氨基葡萄糖片和塞来昔布胶囊顺利中标。目前公司已过评且暂未纳入国采的产品中，阿普米司特片的竞争企业（原研+过评）已达5家及以上。图4：阿普米司特片原研及过评企业情况来源：米内网中国上市药品（MID）数据库阿普米司特由Celgene开发（后被Amgen Inc收购），用于治疗符合接受光疗或系统治疗指征的中度至重度斑块状银屑病的成人患者，原研产品2023年全球销售额已超过20亿美元。原研的阿普米司特片于2021年获批进入中国市场，截至2023年上半年在中国三大终端六大市场的累计销售额已超过2000万元。2023年3月石药集团欧意药业拿下阿普米司特片的国内首仿+首家过评，截至目前已有10家国内药企按新分类获批视同过评。据悉，阿普米司特片在中国的核心专利到期时间为2023年，若该产品顺利纳入第十批国采，江苏正大清江制药将与其他9家“光脚企业”合力抢夺原研药市场，最终鹿死谁手，我们拭目以待。数据来源：米内网数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至3月8日，如有疏漏，欢迎指正。本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦